Edgewise Therapeutics (EWTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Edgewise Therapeutics' (EWTX) quarterly EPS (Weighted Average and Diluted) came in at -$0.46 in Q1 2026, down 6.98% year-on-year from -$0.49 in Q1 2025, and up 4.17% quarter-over-quarter from -$0.48 in Q4 2025.
Edgewise Therapeutics (EWTX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.46 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.46, down 6.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.67 (down 7.74% YoY), and the FY2025 annual result was -$1.63, down 12.41% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.46 for Q1 2026 at Edgewise Therapeutics, up from -$0.48 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.3 in Q1 2022 to a low of -$0.48 in Q4 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.36 (2023), against an average of -$0.38.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 93.14% in 2022 and plunged 56.67% in 2023, its largest moves.
- Edgewise Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.3 in 2022, then sank by 56.67% to -$0.47 in 2023, then gained by 10.64% to -$0.42 in 2024, then fell by 14.29% to -$0.48 in 2025, then climbed by 4.17% to -$0.46 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.46 (Q1 2026), -$0.48 (Q4 2025), and -$0.39 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Edgewise Therapeutics | 3.65 Bn | 3.65 Bn | - | -0.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.46 |
| Dec 31, 2025 | -0.48 |
| Sep 30, 2025 | -0.39 |
| Jun 30, 2025 | -0.34 |
| Mar 31, 2025 | -0.43 |
| Dec 31, 2024 | -0.42 |
| Sep 30, 2024 | -0.36 |
| Jun 30, 2024 | -0.34 |
| Mar 31, 2024 | -0.33 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -0.41 |
| Jun 30, 2023 | -0.34 |
| Mar 31, 2023 | -0.36 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -0.34 |
| Jun 30, 2022 | -0.32 |
| Mar 31, 2022 | -0.30 |
| Dec 31, 2021 | -0.24 |
| Sep 30, 2021 | -0.26 |
| Jun 30, 2021 | -0.21 |